Sanofi (NYSE:SNY) was upgraded by Barclays PLC from an “underweight” rating to an “equal weight” rating in a note issued to investors on Wednesday.

A number of other analysts have also recently weighed in on SNY. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 price objective (up from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. raised Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Finally, Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $53.50.

Sanofi (NYSE:SNY) opened at $44.65 on Wednesday. The stock has a market capitalization of $112,560.12, a P/E ratio of 14.08, a P/E/G ratio of 2.46 and a beta of 0.88. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59. Sanofi has a 12 month low of $38.45 and a 12 month high of $50.65.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.dailypolitical.com/2017/11/15/sanofi-sny-upgraded-to-equal-weight-at-barclays-plc.html.

In related news, major shareholder Sanofi purchased 105,820 shares of the company’s stock in a transaction on Thursday, August 24th. The stock was bought at an average price of $482.04 per share, with a total value of $51,009,472.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.00% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of SNY. Alliancebernstein L.P. lifted its stake in shares of Sanofi by 24.1% in the first quarter. Alliancebernstein L.P. now owns 27,621 shares of the company’s stock worth $1,250,000 after acquiring an additional 5,357 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Sanofi by 3.4% in the first quarter. Geode Capital Management LLC now owns 43,684 shares of the company’s stock worth $1,976,000 after acquiring an additional 1,448 shares in the last quarter. Chemung Canal Trust Co. acquired a new position in shares of Sanofi in the second quarter worth about $268,000. Visionary Asset Management Inc. acquired a new position in shares of Sanofi in the second quarter worth about $322,000. Finally, Aperio Group LLC lifted its stake in shares of Sanofi by 17.8% in the second quarter. Aperio Group LLC now owns 681,230 shares of the company’s stock worth $32,638,000 after acquiring an additional 102,804 shares in the last quarter. Institutional investors own 9.36% of the company’s stock.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.